

## Special Issue

# The Role of Epstein–Barr Virus in Human Cancers

### Message from the Guest Editors

More than 90% of the world's population is infected with the Epstein–Barr virus (EBV), an oncogenic virus aetiologically linked to autoimmune conditions, two pre-malignant lymphoproliferative diseases (LPDs), and up to nine distinct human tumours.

Since its discovery in 1964, evidence indicates that various EBV-encoded proteins, including non-coding RNAs, contribute to developing EBV-associated cancers. Despite more than 60 years of research on EBV, we still lack complete knowledge of the natural history of EBV infection and how the virus interacts with different risk factors to drive the development of cancer.

This Special Issue aims to provide an up-to-date assessment of the current status of our understanding of EBV's contribution to virus-associated malignancies and how this knowledge impacts the diagnosis and treatment of these cancers. To advance the understanding of EBV-related cancers, we welcome the submission of original research and reviews addressing different aspects of EBV infection.

We look forward to receiving your contributions.

---

### Guest Editors

Dr. Lucia Mundo

Dr. Cristiana Bellan

Dr. Stefano Lazzi

---

### Deadline for manuscript submissions

15 September 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/217232](https://mdpi.com/si/217232)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)